QIMR Berghofer

MAP2K1 is a potential therapeutic target in erlotinib resistant head and neck squamous cell carcinoma.


Epidermal growth factor receptor (EGFR) targeted therapies have shown limited efficacy in head and neck squamous cell carcinoma (HNSCC) patients despite its overexpression. Identifying molecular mechanisms associated with acquired resistance to EGFR-TKIs such as erlotinib remains an unmet need and a therapeutic challenge. In this study, we employed an integrated multi-omics approach to delineate mechanisms associated with acquired resistance to erlotinib by carrying out whole exome sequencing, quantitative proteomic and phosphoproteomic profiling. We observed amplification of several genes including AXL kinase and transcription factor YAP1 resulting in protein overexpression. We also observed expression of constitutively active mutant MAP2K1 (p.K57E) in erlotinib resistant SCC-R cells. An integrated analysis of genomic, proteomic and phosphoproteomic data revealed alterations in MAPK pathway and its downstream targets in SCC-R cells. We demonstrate that erlotinib-resistant cells are sensitive to MAPK pathway inhibition. This study revealed multiple genetic, proteomic and phosphoproteomic alterations associated with erlotinib resistant SCC-R cells. Our data indicates that therapeutic targeting of MAPK pathway is an effective strategy for treating erlotinib-resistant HNSCC tumors.

Authors Jain, Ankit P; Patel, Krishna; Pinto, Sneha; Radhakrishnan, Aneesha; Nanjappa, Vishalakshi; Kumar, Manish; Raja, Remya; Patil, Arun H; Kumari, Anjali; Manoharan, Malini; Karunakaran, Coral; Murugan, Saktivel; Keshava Prasad, T S; Chang, Xiaofei; Mathur, Premendu Prakash; Kumar, Prashant; Gupta, Ravi; Gupta, Rohit; Khanna-Gupta, Arati; Sidransky, David; Chatterjee, Aditi; Gowda, Harsha
Pages 18793
Volume 9
Date 1/12/2019
Grant ID
Funding Body Department of Biotechnology (DBT), Government of India
URL http://www.ncbi.nlm.nih.gov/pubmed/?term=10.1038/s41598-019-55208-5